A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss (SURMOUNT-4)
The main purpose is to learn more about how tirzepatide maintains body weight loss. The study has two phases: a lead-in phase in which all participants take tirzepatide and a treatment phase in which participants will either continue tirzepatide or switch to placebo.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have obesity or be overweight
Participants must be overweight and have high blood pressure, high cholesterol, sleep apnea or heart disease
Participants must agree to commit to and undergo study procedures as explained by clinic study staff
Participants Must Not:
Participants must not have diabetes
Participants must not have undergone weight loss surgery (e.g. stomach stapling, lap banding)
Participants must not have lost or gained weight in the last 3 months
Participants must not have chronic kidney disease
Participants must not have made prior suicide attempts
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo